Role of tachykinins as excitatory mediators of NANC contraction in the circular muscle of rat small intestine.
1. The aim of this study was to assess the role of tachykinins, acting via NK1 and NK2 receptors, in mediating nonadrenergic noncholinergic (NANC) contractions produced by electrical field stimulation (EFS) in the circular muscle of the rat small intestine. 2. In the presence of atropine (1 microM), guanethidine (3 microM), indomethacin (10 microM), apamin (0.3 microM) and L-nitroarginine (L-NOARG, 100 microM) and after in vitro capsaicin (10 microM for 15 min) pretreatment, EFS (0.25 ms pulse width, 100 V, 1-30 Hz for 5 s) produced a frequency-dependent NANC contraction of mucosa-free circular muscle strips from the rat proximal duodenum and terminal ileum. In the duodenum, the NANC contraction was preceded by a transient NANC relaxation. All responses to EFS were abolished by 1 microM tetrodotoxin. 3. The NK1 receptor selective antagonist, SR 140,333 (0.1 microM for 60 min) and the NK2 receptor selective antagonist, MEN 10,627 (0.1 microM for 60 min), both produced a partial inhibition of the contractile response to EFS. The co-administration of SR 140,333 and MEN 10,627 produced a profound inhibition of the response to EFS in the duodenum, larger than that produced by each antagonist alone; a fraction (about 25% of the response at 30 Hz) of the NANC contraction of the duodenum persisted in the presence of the two antagonists. This residual response was however abolished after co-administration of the NK1 and NK2 receptor antagonists, GR 94,800 (1 microM) and GR 82,334 (10 microM). The co-administration of SR 140,333 and MEN 10,627 nearly abolished the NANC contraction to EFS in the ileum. 4. Nifedipine (1 microM) induced a profound depression of the NANC contraction to EFS in both duodenal and ileal strips. A fraction of the response to EFS (about 25 and 5-10% of the response at 30 Hz in the duodenum and ileum, respectively) was nifedipine-resistant. SR 140,333 (0.1 microM) had little effect on the nifedipine-resistant response to EFS in the duodenum although it reduced by about 50% the response in the ileum. MEN 10,627 (0.1 microM) produced a partial inhibitory effect of the nifedipine-resistant response in both regions. The co-administration of SR 140,333 and MEN 10,627 nearly abolished the nifedipine-resistant response in the ileum while a small fraction (about 20% of control) of the response persisted in the duodenum.
Maggi
C A
CA
Pharmacology Department, A. Menarini Pharmaceuticals, Florence, Italy.
Giuliani
S
S
D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology; D004386:Duodenum / Q000378:metabolism; D004558:Electric Stimulation; D007082:Ileum / Q000378:metabolism; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects / Q000502:physiology*; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology*; D064729:Neurokinin-1 Receptor Antagonists; D009543:Nifedipine / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D011812:Quinuclidines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D018040:Receptors, Neurokinin-1 / Q000502:physiology*; D018041:Receptors, Neurokinin-2 / Q000037:antagonists & inhibitors / Q000502:physiology*; D015320:Tachykinins / Q000502:physiology*
D002121:Calcium Channel Blockers; D064729:Neurokinin-1 Receptor Antagonists; D010456:Peptides, Cyclic; D010880:Piperidines; D011812:Quinuclidines; D018040:Receptors, Neurokinin-1; D018041:Receptors, Neurokinin-2; D015320:Tachykinins; C085215:SR 140333; C090951:MEN 10627; D009543:Nifedipine